Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000198426
Ethics application status
Approved
Date submitted
4/04/2007
Date registered
11/04/2007
Date last updated
7/04/2009
Type of registration
Prospectively registered
Titles & IDs
Public title
The Australian Sensor-Augmented Pump Algorithm Study
Query!
Scientific title
Evaluation of an Algorithm to
Guide Patients with Type I Diabetes
Treated with Continuous Subcutaneous Insulin Infusion on How to Respond to
Real-Time Continuous Glucose Levels.
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ALG-OS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 1 diabetes
1720
0
Query!
Glycaemic control.
1721
0
Query!
Oxidation
1722
0
Query!
Condition category
Condition code
Metabolic and Endocrine
1813
1813
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Insulin pump therapy with real-time continuous glucose monitoring. Intervention-the provision of an algorithm to guide therapy.Control-No algorithm provided.
The algorithm is a guide advising patients with Type I diabetes managed with pump therapy on how to best respond to the information provided by continuous real-time glucose monitoring. In particular it will advise the patient on how to adjust their insulin dosing in response to glucose levels, glucose trend information, and twenty four hour profiles provided by the continuous monitoring device in both in the short term (reactively) and in the long term (proactively). The study is to be conducted in two 16 week phases. In phase one, those allocated the algorithm will be instructed in its principles which are to be applied throughout this phase of the study. During this period they are to wear the real-time continuous glucose monitoring device for at least 70% of the time. During the second 16 week phase of the study, those who had previously been allocated the algorithm will return to usual care ie insulin pump without real-time glucose monitoring. The patients will retain the principles of the algorithm to a varying extent. What is learned in the first phase of the study may provide a benefit with regard to glycaemic control that extends beyond the period of real-time monitoring and this hypothesis is to be tested in the second phase of the study. Those subjects randomised to the arm of the study where no algorithm has been provided in the first phase will receive the algorithm at the start of the second 16 week phase. Any shortcomings noted while the algorithm is being implemented during the first phase are to be addressed prior to the provision of the algorithm to those patients who were not randomised to the algorithm arm in phase one.
All patients regardless as to whether they are randomised to the algorithm or not will receive instructions on how to operate the insulin pump device and the real time monitor. An accredited pump trainer and diabetes nurse educator will be responsible for this aspect of the education of the patients who take part in the study. In particular instructions will be provided regarding operation of the menu and buttons of the pump, care of the transmitter, and insertion and care of the sensor. Medical follow up apart from the above and provision of the algorithm in those randomised to the relevant arm of the study will be as per routine care for all patients established on insulin pumps at each of the hospitals taking part in the study.
The total duration of the study is to be encompassed by a 2 week run-in phase, and the two phases each of 16 week duration making a total of 34 weeks.
Query!
Intervention code [1]
1613
0
Treatment: Devices
Query!
Comparator / control treatment
Control-No algorithm provided.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
2534
0
Time spent within the euglycaemic range.The primary outcome is to be determined by three continuous glucose monitoring studies each of six day duration
Query!
Assessment method [1]
2534
0
Query!
Timepoint [1]
2534
0
Following screening prior to randomisation, 16 weeks and 32 weeks.
Query!
Secondary outcome [1]
4381
0
Time spent within the hyperglycaemic range.
Query!
Assessment method [1]
4381
0
Query!
Timepoint [1]
4381
0
Baseline, 16 weeks and 32 weeks.
Query!
Secondary outcome [2]
4382
0
Time spent within the hypoglycaemic range.
Query!
Assessment method [2]
4382
0
Query!
Timepoint [2]
4382
0
Baseline, 16 weeks and 32 weeks.
Query!
Secondary outcome [3]
4383
0
Glycosylated Haemoglobin.
Query!
Assessment method [3]
4383
0
Query!
Timepoint [3]
4383
0
Baseline, 16 weeks and 32 weeks.
Query!
Secondary outcome [4]
4384
0
Glycaemic variability.
Query!
Assessment method [4]
4384
0
Query!
Timepoint [4]
4384
0
Baseline, 16 weeks and 32 weeks.
Query!
Secondary outcome [5]
4385
0
Quality of Life Score.
Query!
Assessment method [5]
4385
0
Query!
Timepoint [5]
4385
0
Baseline, 16 weeks and 32 weeks.
Query!
Eligibility
Key inclusion criteria
Type I diabetes (c-peptide negative)- English speaking. Established on pump therapy for at least 3 months and be proficient in the use of an insulin dose calculator. -Proficient at and committed to at least four fingerprick glucose measurements per day.-Willing to use MiniMed MMT 722 glucose sensor >70% of study time period.-Current HbA1c of <9.5% -All should have access to electronic communication ie email.
Query!
Minimum age
13
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Visual Impairment such that the patient is unable to see the screen or fill the reservoir of the CSII device, or read a glucometer display or administer insulin safely using a pen device.- Intellectual or language difficulties such that operation of a CGM or CSII device is precluded.-Significant renal impairment (eGFR <60 mL/min/1.73 m2 )-Eating Disorders.-Major Psychiatric Disorders.-Life threatening illness (eg myocardial infarct) within last three months.- Steroid therapy or the presence of disease states likely to require future steroid therapy.-Abnormal thyroid function.-A history of gastroparesis or delayed gastric emptying.-Untreated/ inadequately treated coeliac disease.-Pregnancy. For women of childbearing age appropriate contraceptive measures should be taken.- A documented history of insulin allergy/ antibodies.-Patients with haemoglobinopathies or patients requiring regular transfusions.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible subjects are to be selected from site databases and contacted by the investigators at each site. Allocation will involve contacting the holder of the allocation schedule who will be at central administration.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by coin-tossing.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/07/2007
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
1965
0
Commercial sector/Industry
Query!
Name [1]
1965
0
Medtronic
Query!
Address [1]
1965
0
97 Waterloo Road,
North Ryde NSW 2113
Australia
Query!
Country [1]
1965
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
St Vincents Hospital Melbourne
Query!
Address
University of Melbourne, Dept of Medicine, St Vincent's Hospital, Fitzroy 3065, Vic Australia.
Query!
Country
Australia
Query!
Secondary sponsor category [1]
1774
0
Hospital
Query!
Name [1]
1774
0
Royal Childrens Hospital Melbourne
Query!
Address [1]
1774
0
Flemington Rd, Parkville, Victoria, Australia
Query!
Country [1]
1774
0
Australia
Query!
Secondary sponsor category [2]
1775
0
Hospital
Query!
Name [2]
1775
0
Royal Melbourne Hospital
Query!
Address [2]
1775
0
Royal Parade, Parkville, Victoria, Australia
Query!
Country [2]
1775
0
Australia
Query!
Secondary sponsor category [3]
1776
0
Hospital
Query!
Name [3]
1776
0
Western General Hospital Melbourne
Query!
Address [3]
1776
0
Gordon st. Footscray, Victoria, Australia
Query!
Country [3]
1776
0
Australia
Query!
Secondary sponsor category [4]
1777
0
Hospital
Query!
Name [4]
1777
0
Monash Medical Centre Clayton
Query!
Address [4]
1777
0
Clayton rd Clayton, Victoria, Australia
Query!
Country [4]
1777
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
3659
0
St Vincent's Hospital Melbourne
Query!
Ethics committee address [1]
3659
0
Victoria Pde Fitzroy, Victoria,3065
Query!
Ethics committee country [1]
3659
0
Australia
Query!
Date submitted for ethics approval [1]
3659
0
Query!
Approval date [1]
3659
0
01/07/2007
Query!
Ethics approval number [1]
3659
0
Query!
Ethics committee name [2]
3660
0
Royal Melbourne Hospital
Query!
Ethics committee address [2]
3660
0
Query!
Ethics committee country [2]
3660
0
Australia
Query!
Date submitted for ethics approval [2]
3660
0
Query!
Approval date [2]
3660
0
Query!
Ethics approval number [2]
3660
0
Query!
Summary
Brief summary
In patients with Type 1 diabetes the body does not produce any insulin. Insulin is a hormone that the body (pancreas) produces. Insulin is essential for life; In a healthy body the pancreas produces insulin continuously all day to keep blood sugar in a healthy range to allow us to do all activities that do not require eating such as walking, talking, sleeping. In the event of eating the pancreas automatically produces an extra amount of Insulin on demand when food is consumed. Foods such as carbohydrates and starches are processed by the body into sugar in the bloodstream. The hormone Insulin stabilizes blood sugar to a healthy range so that there is not too much or too little sugar in the blood. In a diabetic maintaining this balance is difficult because the pancreas is not producing any insulin. As such external insulin must be administered. The results of a landmark study known as the Diabetes Control and Complications Trial (DCCT) demonstrated that strict blood sugar control reduced the development of complications in patients with Type I diabetes like strokes, kidney and eye disease. An ideal solution in these patients would be the replacement of insulin in a manner identical to that in the healthy state. At present the two main options for patients, both of which deliver insulin through injections, are multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) via a mechanical device usually referred to as a “pump.” CSII or the “pump” delivers insulin in a flexible and precisely controlled manner via a programmable pager sized device with an insulin reservoir. Insulin delivery rates can be varied according to the time of day, and reduced temporarily during periods of exercise. A patient-initiated dose of insulin can be delivered in a variety of profiles aimed to match the nature of the ingested meal. Recently a combination real-time Continuous (blood) Glucose Monitoring/ CSII “pump” device has become available (Paradigm? Real-time system / MMT 722, Medtronic, Minimed, Northridge CA) and is the first such pump commercially available worldwide. The ultimate aim in the management of patients with Type I diabetes is the attainment of stable blood glucose, as this strategy will prevent the development of complications. The above product is instrumental to this. However, preliminary data suggests that the employment of real-time system “pump” in the absence of a patient education program may not result in an improvement in glycaemic control. An algorithm informing and educating the patient on how to deal with the information provided by this new technology will be analysed as part of this study. In addition a blood test known as Hba1c will also be performed. This blood test measures on average a patient’s blood glucose control over a three month span. Quality of Life Questionnaires will also be used to assess whether diabetes has impacted of every day life and activities. Five sites across Melbourne have been selected to take part. The principle Investigators are at St Vincent’s Adults public Hospital. The other sites involved are: The Western General Hospital, Monash Medical Centre, The Royal Children’s Hospital and The Royal Melbourne Hospital.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
27547
0
Query!
Address
27547
0
Query!
Country
27547
0
Query!
Phone
27547
0
Query!
Fax
27547
0
Query!
Email
27547
0
Query!
Contact person for public queries
Name
10802
0
Dr David Norman O'Neal
Query!
Address
10802
0
Department of Medicine (St. Vincent’s Hospital)
Clinical Science Building
St Vincent’s Hospital
Cnr. Princes and Regent Streets
Fitzroy, Melbourne VIC 3065
Query!
Country
10802
0
Australia
Query!
Phone
10802
0
+ 61 3 9288 2574
Query!
Fax
10802
0
+61 3 9288 2581
Query!
Email
10802
0
[email protected]
Query!
Contact person for scientific queries
Name
1730
0
Dr David Norman O'Neal
Query!
Address
1730
0
Department of Medicine (St. Vincent’s Hospital)
Clinical Science Building
St Vincent’s Hospital
Cnr. Princes and Regent Streets
Fitzroy Melbourne VIC 3065
Query!
Country
1730
0
Australia
Query!
Phone
1730
0
+ 61 3 9288 2574
Query!
Fax
1730
0
+61 3 9288 2581
Query!
Email
1730
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose Levels A randomized controlled trial
2010
https://doi.org/10.2337/dc09-1481
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF